Vancouver-based Absci to send first drug to clinical trials in what CEO calls a ‘huge milestone’
The company also announced a collaboration with chipmaker AMD to power its advanced de novo AI antibody design models, as well as AI biotechnology company Owkin to co-develop therapeutic candidates ...
Unveiled updates across proprietary pipeline and demonstrated new breakthroughs by AI platform at 2024 R&D Day Entered into collaboration with AMD, including $20 million strategic investment in Absci ...
We recently published a list of the 7 Most Undervalued Biotech Stocks To Invest In. In this article, we are going to take a ...
Conduit Pharmaceuticals advances its pipeline with key progress in preclinical lupus studies for AZD5658, Phase IIa trial design for AZD1656, ...
We came across a bullish thesis on Genmab A/S (GMAB) on Substack by Oliver | MMMT Wealth. In this article, we will summarize ...
We recently published a list of the 7 Most Undervalued Biotech Stocks To Invest In. In this article, we are going to take a ...
New active ingredients such as antibodies are usually tested individually in laboratory animals. Researchers have now developed a technology that can be used to test around 25 antibodies ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback